HLB Pharmaceutical Co. Ltd (047920) — Capital Reinvestment Ratio
Latest as of September 2025:
1.21x
HLB Pharmaceutical Co. Ltd (047920) has a Capital Reinvestment Ratio of 1.21x as of September 2025, meaning it reinvests 1% of its operating cash flow (₩1.86 Billion) in capital expenditures (₩2.26 Billion). See HLB Pharmaceutical Co. Ltd free cash flow ratio to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
1.21x
Capex / Operating Cash Flow
Operating Cash Flow
₩1.86 Billion
KRW
Capital Expenditures
₩2.26 Billion
KRW
Data as of
Sep 2025
Most recent filing
HLB Pharmaceutical Co. Ltd Capital Reinvestment Ratio (2014–2024)
This chart tracks HLB Pharmaceutical Co. Ltd's Capital Reinvestment Ratio across 3 annual periods.
Annual Capital Reinvestment Ratio for HLB Pharmaceutical Co. Ltd (2014–2024)
Year-by-year Capital Reinvestment Ratio for HLB Pharmaceutical Co. Ltd from 2014 to 2024. For live market cap and broader valuation context, see HLB Pharmaceutical Co. Ltd market cap and net worth.
| Year | Reinvestment Ratio | Operating CF (KRW) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2024 | 0.45x | ₩6.84 Billion | ₩3.09 Billion | ▼ -56.2% |
| 2019 | 1.03x | ₩1.35 Billion | ₩1.40 Billion | ▼ -29.6% |
| 2014 | 1.47x | ₩1.54 Billion | ₩2.26 Billion | — |
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow